A downtrend has been apparent in Intellia Therapeutics, Inc. (NTLA) lately with too much selling pressure. The stock has declined 19.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical ...